scholarly journals MP80-03 PROGNOSTIC DIFFERENCES AND SURVIVAL OUTCOMES IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA SUBTYPES – A COMPARISON BETWEEN TYPE I VS. TYPE II

2020 ◽  
Vol 203 ◽  
pp. e1225
Author(s):  
Giuseppe Rosiello* ◽  
Fabio Muttin ◽  
Alessandro Nini ◽  
Gianfranco Baiamonte ◽  
Carlo Andrea Bravi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Survival Outcomes ◽  
Type I ◽  
Type Ii

scholarly journals The effect of the papillary renal cell carcinoma subtype on oncological outcomes

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Honghong Pan ◽  
Liefu Ye ◽  
Qingguo Zhu ◽  
Zesong Yang ◽  
Minxiong Hu
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Clinicopathological Features ◽  
Type I ◽  
Type Ii ◽  
Oncological Outcomes ◽  
Stage Grouping ◽  
Surgical Methods

AbstractThe study aimed to compare the clinicopathological features and prognosis between type I and type II papillary renal cell carcinoma (PRCC) and to investigate whether the subtypes of PRCC would affect oncological outcomes. A total of 102 patients with PRCC were recruited, of which 42 were type I PRCC and 60 type II. The clinicopathological features and oncologic outcomes of the patients were evaluated. The type II cases had a higher WHO/ISUP grading (P < 0.001), T (P = 0.003), N (P = 0.010) stage and stage grouping (P = 0.011) than the type I. During a median follow-up period of 61.4 months, 1-year cancer specific survival (CSS) of the type I was 100%, 5-year CSS was 95.2%, the 1-year CSS of the type II was 96.2%, and 5-year CSS was 75.7%. The univariate analysis showed that subtype, symptoms, TNM, stage grouping, WHO/ISUP grading and surgical methods appeared to affect prognosis of the patients with PRCC. However, multivariate analysis revealed that only stage grouping was the independent risk factor. After the stage grouping factor was adjusted for the analysis, there were no statistically significant differences in CSS (P = 0.214) and PFS (P = 0.190) between the localized type I and type II PRCC groups. Compared with type I PRCC, type II had higher pathological T, N stage and WHO/ISUP grading. However, it was the Stage grouping that made a great difference to oncological outcomes, rather than the subtype of PRCC.

scholarly journals Focal Segmental Glomerulosclerosis Preceding Type 2 Papillary Renal Cell Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Dominik Dabrowski ◽  
Ekin Ozluk ◽  
Silvia Barbeito ◽  
Eric X. Wei
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Focal Segmental Glomerulosclerosis ◽  
Paraneoplastic Syndrome ◽  
Renal Cell ◽  
Renal Mass ◽  
Papillary Renal Cell Carcinoma ◽  
Type I ◽  
Type Ii ◽  
Segmental Glomerulosclerosis

Renal cell carcinoma (RCC) is the predominant renal malignancy in adults. Of the four general subtypes, papillary renal cell carcinoma (P-RCC) is the second most common and can be subdivided into type I, type II, and a mixture of type I and II. Focal segmental glomerulosclerosis (FSGS) is the most common glomerulopathy at all ages, and it can be seen as a paraneoplastic syndrome. RCC, in general, is known to present with many paraneoplastic syndromes, and glomerulopathies are among these. Rarely, RCC and glomerulopathies may overlap in the same patient. Here, we report a 58-year-old male with a past medical history of FSGS and chronic kidney disease (CKD), stage III, who was found to have an incidental renal mass that was later diagnosed as type II P-RCC. The histology showed pseudostratified tumor cells with an eosinophilic cytoplasm that formed papillary configurations and displayed areas of necrosis. The prior FSGS diagnosis exhibited segmental sclerosis, refractory tufts, and capillary membrane wrinkling. A period of 1.5 years elapsed between the diagnosis of the glomerulopathy and the malignancy. The tumor was found to be at stage TIb. To our knowledge, this may be the first reported case of usual-type FSGS as paraneoplastic glomerulopathy (PG) preceding P-RCC. Because FSGS only sparingly affects the kidney and is a common glomerulopathy in adults, it is reasonable to complete comprehensive diagnostic studies and commence medically necessary treatment, especially in the background of other renal comorbidities. These preexisting comorbidities may be associated with malignancy very early in its course. The probability of RCC-associated paraneoplastic glomerulopathy is low, which means an already incidentally found renal mass may conceal a serpentine paraneoplastic syndrome. A more developed understanding of these manifestations can lead experienced clinicians to suspect and possibly uncover an insidious RCC before it advances.

scholarly journals Differences Between Type I and Type II Papillary Renal Cell Carcinoma on Ultrasound

2019 ◽  
Vol 3 (4) ◽  
pp. 187
Author(s):  
Zhang, MD Qing ◽  
Wei, MD Shuping ◽  
Yang, MD Bin ◽  
Qian, MD Xiaoqin
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Type I ◽  
Type Ii

scholarly journals Papillary renal cell carcinoma: what is missing in research? A case report and a review of literature

2019 ◽  
Vol 7 ◽  
pp. 2050313X1986947 ◽  
Author(s):  
Ihab Eldessouki ◽  
Ola Gaber ◽  
Mahmoud A Shehata ◽  
Tariq Namad ◽  
Joseph Atallah ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Growth Factor Receptor ◽  
Papillary Renal Cell Carcinoma ◽  
Type I ◽  
Renal Cell Carcinomas ◽  
Cancer Statistics ◽  
Male Predominance ◽  
Endothelial Growth Factor

The incidence of renal cell carcinomas in adults ranges has been increasing over the past decades in both men and women. Once the incidence was 2.9%, now is reported to have increased to 3%–5% with male predominance according to the most recent reports of cancer statistics. The disease typically describes a group of different histopathological subtypes; the most common is clear cell carcinoma which accounts for 70%–80% of the diagnosed cases, while papillary renal cell carcinoma and chromophobe types represent 20% and 5%, respectively. In 1996, the renal cell carcinomas Heidelberg classification was introduced by Delahunt et al. It divides renal cell tumors into benign and malignant parenchymal neoplasms, excluding Wilm’s tumor and secondary metastases and limiting each subcategory to the most commonly documented genetic abnormalities, if applicable. In this report, we discuss a case of metastatic type I papillary renal cell carcinoma treated with the anti-vascular endothelial growth factor receptor sunitinib and showing marked long-term clinical response. Through this case, we highlight the importance of re-classifying papillary renal cell carcinoma subtypes to prioritize the clinical management of these cases.

scholarly journals Type II papillary renal cell carcinoma with heterotrophic ossification: a case report

2018 ◽  
Vol 100 (3) ◽  
pp. e49-e50
Author(s):  
T Jindal ◽  
N Jain ◽  
A Agarwal
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Type Ii ◽  
Renal Cell Carcinomas ◽  
Unique Case

Heterotrophic ossification in tumours is an uncommon phenomenon. The presence of ossification in renal cell carcinomas is extremely rare. In this report, we present a unique case of type II papillary renal cell carcinoma associated with heterotrophic ossification.

scholarly journals Robot-Assisted Retroperitoneal Lymphadenectomy In A Patient With Type I Papillary Renal Cancer Recurrence After Five Years Of Follow-Up: A Case Report.

2020 ◽  
Author(s):  
Yazan AL SALHI ◽  
Andrea FUSCHI ◽  
Gennaro VELOTTI ◽  
Lorenzo CAPONE ◽  
Sara AVERSA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cancer ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Surgical Excision ◽  
Histopathological Diagnosis ◽  
Type I ◽  
Retroperitoneal Lymphadenectomy

Abstract INTRODUCTION: Papillary renal cell carcinoma is a rare cancer and is the second most frequent histologic type among all renal cell carcinoma, accounting for up to 15%. Patients with type 1 PRCC are diagnosed at a lower stage and present a lower nuclear grade compared to type 2.CASE PRESENTATION: A 72-year-old man underwent a right radical nephrectomy 7 years ago for a 10 cm mesorenal mass with a final histopathological diagnosis of a papillary renal cell carcinoma type 1 pT2a with negative surgical margins.Five years after the surgery, computed tomography (CT) scan imaging showed the presence of multiple masses suspicious for node recurrences disease localized in the renal lodge, in the inter-aorto-caval space, at the iliac vessel bifurcation and right common iliac vessels. Patient underwent a robotic retroperitoneal lymphadenectomy. The operative time was 114 min, estimated blood loss 200 ml; length of hospital stay 4 days. The abdominal drainage was removed at first post-operative day. No perioperative complications. The removed lesions confirmed on histopathological examination the recurrence of type I papillary renal cancer at: renal lodge, inter-aorto-caval space, iliac bifurcation, common iliac lymph nodes. No further recurrences on surveillance imaging 24 months after his procedure.DISCUSSION AND CONCLUSION: We present the first description of minimally invasive surgical excision for a papillary type I renal cancer nodal recurrence and renal fossa recurrence.Our present study shows that patients treated with surgical excision for isolated RPLN recurrences may afford select patient durable cancer control.The robotic approach can be offered as an effective modality of treatment in this rare case of type I papillary renal cancer metastases.The extent of resection, as well as the optimal integration of surgery and systemic therapy, remain to be determined in this setting.

Sign in / Sign up

Export Citation Format

Share Document